GEORGETTE PMHNP Exam Review with Verified
Questions & Answers with Detailed Rationales |
Complete Study Guide | A+
Psychiatric-Mental Health Nurse Practitioner | Comprehensive Board Review
,COMPLETE COVERAGE:
➢ Test-Taking Strategies & ADPIER Framework
➢ Mood Stabilizers: Lithium, Depakote, Lamictal, Tegretol, Clozapine
➢ Teratogenic Risks & Pregnancy Safety
➢ CYP450 Drug Interactions (Inducers & Inhibitors)
➢ Neuroanatomy, Brain Lobes & Neurotransmitters
➢ Dopamine Pathways & EPS Management
➢ NMS, Serotonin Syndrome & Hypertensive Crisis
➢ Eating Disorders, Neurocognitive Disorders & Delirium
➢ Substance Use Disorders, CIWA, COWS & Screening Tools
➢ Developmental Theories: Erikson, Piaget, Freud
➢ Suicide Risk, Therapeutic Relationship & Motivational Interviewing
➢ ADHD, Pediatric Psychiatry & Personality Disorders
➢ Depression, Bipolar Disorder & Rating Scales
➢ Anxiety, PTSD & Complete Q&A Bank with Answers
,Table of Contents
Table of Contents ..................................................................................................................................................... 3
SECTION 1: TEST-TAKING STRATEGIES & ADPIER FRAMEWORK ............................................................ 6
1.1 Core Test-Taking Principles ........................................................................................................................... 6
1.2 ADPIER Clinical Framework ......................................................................................................................... 6
SECTION 2: MOOD STABILIZERS — COMPLETE REFERENCE .................................................................... 7
2.1 Lithium — Gold Standard .............................................................................................................................. 7
2.2 Depakote (Divalproex Sodium / Valproic Acid) ............................................................................................ 8
2.3 Lamotrigine (Lamictal) .................................................................................................................................. 9
2.4 Carbamazepine (Tegretol) ............................................................................................................................ 10
2.5 Clozapine (Clozaril) — Special Monitoring ................................................................................................. 10
SECTION 3: TERATOGENIC RISKS & PREGNANCY SAFETY ..................................................................... 12
SECTION 4: CYP450 DRUG INTERACTIONS .................................................................................................. 13
4.1 Core Concepts .............................................................................................................................................. 13
4.2 CYP INDUCERS — BS CRAP GPS (decrease levels) ................................................................................ 13
4.3 CYP INHIBITORS — SICKFACES.COM (increase levels) ....................................................................... 13
4.4 Meds That Cause MANIA............................................................................................................................ 14
4.5 Meds That Cause DEPRESSION ................................................................................................................. 14
SECTION 5: PHARMACOKINETICS & PHARMACODYNAMICS ................................................................. 15
5.1 Core Definitions ........................................................................................................................................... 15
5.2 Elderly & Psychotropic Risks ....................................................................................................................... 15
SECTION 6: NEUROANATOMY & NEUROTRANSMITTERS ........................................................................ 16
6.1 Brain Lobes & Functions.............................................................................................................................. 16
6.2 The Limbic System ...................................................................................................................................... 16
6.3 Neurotransmitters — Complete Reference ................................................................................................... 17
6.4 Dopamine Pathways — HIGH YIELD......................................................................................................... 17
SECTION 7: EXTRAPYRAMIDAL SIDE EFFECTS (EPS) ................................................................................ 19
7.1 EPS Overview .............................................................................................................................................. 19
7.2 Neuroleptic Malignant Syndrome (NMS)..................................................................................................... 19
7.3 Serotonin Syndrome ..................................................................................................................................... 20
7.4 Hypertensive Crisis — MAOIs .................................................................................................................... 21
SECTION 8: EATING DISORDERS .................................................................................................................... 23
8.1 Anorexia Nervosa vs. Bulimia Nervosa........................................................................................................ 23
SECTION 9: NEUROCOGNITIVE & DEMENTIA DISORDERS ...................................................................... 24
9.1 Delirium vs. Dementia vs. Pseudodementia ................................................................................................. 24
9.2 Types of Dementia ....................................................................................................................................... 24
SECTION 10: SUBSTANCE USE DISORDERS & WITHDRAWAL ................................................................. 26
10.1 Alcohol Use Disorder ................................................................................................................................. 26
, 10.2 Opioid Use Disorder ................................................................................................................................... 27
10.3 Screening Tools .......................................................................................................................................... 28
SECTION 11: DEVELOPMENTAL THEORIES ................................................................................................. 29
11.1 Erikson's Psychosocial Stages .................................................................................................................... 29
11.2 Piaget's Cognitive Stages ............................................................................................................................ 29
11.3 Freud's Psychosexual Stages ...................................................................................................................... 29
SECTION 12: SUICIDE RISK & THERAPEUTIC RELATIONSHIP ................................................................. 31
12.1 Suicide Risk Factors ................................................................................................................................... 31
12.2 Clinical Priority in Suicidal Situations ....................................................................................................... 31
12.3 Therapeutic Relationship ............................................................................................................................ 32
SECTION 13: MOTIVATIONAL INTERVIEWING & TRANSTHEORETICAL MODEL ................................ 33
13.1 Motivational Interviewing Core ................................................................................................................. 33
13.2 Transtheoretical Model of Change ............................................................................................................. 33
SECTION 14: ANXIETY, PTSD, OCD & PERSONALITY DISORDERS .......................................................... 34
14.1 Anxiety Disorders....................................................................................................................................... 34
14.2 PTSD .......................................................................................................................................................... 34
14.3 OCD & Related Disorders .......................................................................................................................... 34
14.4 Personality Disorders — Clusters ............................................................................................................... 34
SECTION 15: ADHD & PEDIATRIC PSYCHIATRY ......................................................................................... 36
15.1 ADHD Overview ........................................................................................................................................ 36
15.2 Pediatric Diagnoses .................................................................................................................................... 36
SECTION 16: DEPRESSION & BIPOLAR DISORDER ..................................................................................... 38
16.1 Major Depressive Disorder (MDD) ............................................................................................................ 38
16.2 Bipolar Disorder ......................................................................................................................................... 38
SECTION 17: SCHIZOPHRENIA & PSYCHOTIC DISORDERS ....................................................................... 40
17.1 Schizophrenia Overview............................................................................................................................. 40
SECTION 18: RATING SCALES — COMPLETE REFERENCE ....................................................................... 41
18.1 Depression Scales ....................................................................................................................................... 41
18.2 Anxiety Scales ............................................................................................................................................ 41
18.3 Cognitive Assessment Scales ..................................................................................................................... 41
18.4 Withdrawal Scales ...................................................................................................................................... 42
SECTION 19: THYROID FUNCTION & PSYCHIATRIC MIMICS ................................................................... 43
SECTION 20: LEVELS OF PREVENTION ......................................................................................................... 44
SECTION 21: COMPLETE Q&A BANK WITH ANSWER KEY ....................................................................... 45
21.1 Pharmacology Q&A ................................................................................................................................... 45
21.2 Neuroscience Q&A .................................................................................................................................... 46
21.3 Clinical Scenario Q&A — HIGH YIELD .................................................................................................. 46
SECTION 22: HIGH-YIELD MNEMONICS & QUICK REFERENCE ............................................................... 49
22.1 Essential Mnemonics .................................................................................................................................. 49
Questions & Answers with Detailed Rationales |
Complete Study Guide | A+
Psychiatric-Mental Health Nurse Practitioner | Comprehensive Board Review
,COMPLETE COVERAGE:
➢ Test-Taking Strategies & ADPIER Framework
➢ Mood Stabilizers: Lithium, Depakote, Lamictal, Tegretol, Clozapine
➢ Teratogenic Risks & Pregnancy Safety
➢ CYP450 Drug Interactions (Inducers & Inhibitors)
➢ Neuroanatomy, Brain Lobes & Neurotransmitters
➢ Dopamine Pathways & EPS Management
➢ NMS, Serotonin Syndrome & Hypertensive Crisis
➢ Eating Disorders, Neurocognitive Disorders & Delirium
➢ Substance Use Disorders, CIWA, COWS & Screening Tools
➢ Developmental Theories: Erikson, Piaget, Freud
➢ Suicide Risk, Therapeutic Relationship & Motivational Interviewing
➢ ADHD, Pediatric Psychiatry & Personality Disorders
➢ Depression, Bipolar Disorder & Rating Scales
➢ Anxiety, PTSD & Complete Q&A Bank with Answers
,Table of Contents
Table of Contents ..................................................................................................................................................... 3
SECTION 1: TEST-TAKING STRATEGIES & ADPIER FRAMEWORK ............................................................ 6
1.1 Core Test-Taking Principles ........................................................................................................................... 6
1.2 ADPIER Clinical Framework ......................................................................................................................... 6
SECTION 2: MOOD STABILIZERS — COMPLETE REFERENCE .................................................................... 7
2.1 Lithium — Gold Standard .............................................................................................................................. 7
2.2 Depakote (Divalproex Sodium / Valproic Acid) ............................................................................................ 8
2.3 Lamotrigine (Lamictal) .................................................................................................................................. 9
2.4 Carbamazepine (Tegretol) ............................................................................................................................ 10
2.5 Clozapine (Clozaril) — Special Monitoring ................................................................................................. 10
SECTION 3: TERATOGENIC RISKS & PREGNANCY SAFETY ..................................................................... 12
SECTION 4: CYP450 DRUG INTERACTIONS .................................................................................................. 13
4.1 Core Concepts .............................................................................................................................................. 13
4.2 CYP INDUCERS — BS CRAP GPS (decrease levels) ................................................................................ 13
4.3 CYP INHIBITORS — SICKFACES.COM (increase levels) ....................................................................... 13
4.4 Meds That Cause MANIA............................................................................................................................ 14
4.5 Meds That Cause DEPRESSION ................................................................................................................. 14
SECTION 5: PHARMACOKINETICS & PHARMACODYNAMICS ................................................................. 15
5.1 Core Definitions ........................................................................................................................................... 15
5.2 Elderly & Psychotropic Risks ....................................................................................................................... 15
SECTION 6: NEUROANATOMY & NEUROTRANSMITTERS ........................................................................ 16
6.1 Brain Lobes & Functions.............................................................................................................................. 16
6.2 The Limbic System ...................................................................................................................................... 16
6.3 Neurotransmitters — Complete Reference ................................................................................................... 17
6.4 Dopamine Pathways — HIGH YIELD......................................................................................................... 17
SECTION 7: EXTRAPYRAMIDAL SIDE EFFECTS (EPS) ................................................................................ 19
7.1 EPS Overview .............................................................................................................................................. 19
7.2 Neuroleptic Malignant Syndrome (NMS)..................................................................................................... 19
7.3 Serotonin Syndrome ..................................................................................................................................... 20
7.4 Hypertensive Crisis — MAOIs .................................................................................................................... 21
SECTION 8: EATING DISORDERS .................................................................................................................... 23
8.1 Anorexia Nervosa vs. Bulimia Nervosa........................................................................................................ 23
SECTION 9: NEUROCOGNITIVE & DEMENTIA DISORDERS ...................................................................... 24
9.1 Delirium vs. Dementia vs. Pseudodementia ................................................................................................. 24
9.2 Types of Dementia ....................................................................................................................................... 24
SECTION 10: SUBSTANCE USE DISORDERS & WITHDRAWAL ................................................................. 26
10.1 Alcohol Use Disorder ................................................................................................................................. 26
, 10.2 Opioid Use Disorder ................................................................................................................................... 27
10.3 Screening Tools .......................................................................................................................................... 28
SECTION 11: DEVELOPMENTAL THEORIES ................................................................................................. 29
11.1 Erikson's Psychosocial Stages .................................................................................................................... 29
11.2 Piaget's Cognitive Stages ............................................................................................................................ 29
11.3 Freud's Psychosexual Stages ...................................................................................................................... 29
SECTION 12: SUICIDE RISK & THERAPEUTIC RELATIONSHIP ................................................................. 31
12.1 Suicide Risk Factors ................................................................................................................................... 31
12.2 Clinical Priority in Suicidal Situations ....................................................................................................... 31
12.3 Therapeutic Relationship ............................................................................................................................ 32
SECTION 13: MOTIVATIONAL INTERVIEWING & TRANSTHEORETICAL MODEL ................................ 33
13.1 Motivational Interviewing Core ................................................................................................................. 33
13.2 Transtheoretical Model of Change ............................................................................................................. 33
SECTION 14: ANXIETY, PTSD, OCD & PERSONALITY DISORDERS .......................................................... 34
14.1 Anxiety Disorders....................................................................................................................................... 34
14.2 PTSD .......................................................................................................................................................... 34
14.3 OCD & Related Disorders .......................................................................................................................... 34
14.4 Personality Disorders — Clusters ............................................................................................................... 34
SECTION 15: ADHD & PEDIATRIC PSYCHIATRY ......................................................................................... 36
15.1 ADHD Overview ........................................................................................................................................ 36
15.2 Pediatric Diagnoses .................................................................................................................................... 36
SECTION 16: DEPRESSION & BIPOLAR DISORDER ..................................................................................... 38
16.1 Major Depressive Disorder (MDD) ............................................................................................................ 38
16.2 Bipolar Disorder ......................................................................................................................................... 38
SECTION 17: SCHIZOPHRENIA & PSYCHOTIC DISORDERS ....................................................................... 40
17.1 Schizophrenia Overview............................................................................................................................. 40
SECTION 18: RATING SCALES — COMPLETE REFERENCE ....................................................................... 41
18.1 Depression Scales ....................................................................................................................................... 41
18.2 Anxiety Scales ............................................................................................................................................ 41
18.3 Cognitive Assessment Scales ..................................................................................................................... 41
18.4 Withdrawal Scales ...................................................................................................................................... 42
SECTION 19: THYROID FUNCTION & PSYCHIATRIC MIMICS ................................................................... 43
SECTION 20: LEVELS OF PREVENTION ......................................................................................................... 44
SECTION 21: COMPLETE Q&A BANK WITH ANSWER KEY ....................................................................... 45
21.1 Pharmacology Q&A ................................................................................................................................... 45
21.2 Neuroscience Q&A .................................................................................................................................... 46
21.3 Clinical Scenario Q&A — HIGH YIELD .................................................................................................. 46
SECTION 22: HIGH-YIELD MNEMONICS & QUICK REFERENCE ............................................................... 49
22.1 Essential Mnemonics .................................................................................................................................. 49
